Phaseline

Targets › FNTB

FNTB (Protein farnesyltransferase subunit beta): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Sep 2027.

Essential subunit of the farnesyltransferase complex. Catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. (UniProt, P49356)

Open in Phaseline: the race on FNTB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Tipifarnib
Protein farnesyltransferase inhibitor
FNTA, FNTBPhase 2Malignant Solid NeoplasmSep 2027
Giselle ShollerTipifarnib
Protein farnesyltransferase inhibitor
FNTA, FNTBPhase 2NeuroblastomaDec 2030

Conditions

Malignant Solid Neoplasm (1) Neuroblastoma (1)

Modalities

small molecule (1), mixed (1)

Companies

National Cancer Institute (NCI) (1) Giselle Sholler (1)

Related targets

FNTA (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.